These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 6938020)

  • 21. Multivariate analysis of prognostic factors in patients with advanced prostatic cancer: results from 2 European Organization for Research on Treatment of Cancer trials.
    de Voogt HJ; Suciu S; Sylvester R; Pavone-Macaluso M; Smith PH; de Pauw M
    J Urol; 1989 Apr; 141(4):883-8. PubMed ID: 2522561
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EMP combination chemotherapy and low-dose monotherapy in advanced prostate cancer.
    Kitamura T; Nishimatsu H; Hamamoto T; Tomita K; Takeuchi T; Ohta N
    Expert Rev Anticancer Ther; 2002 Feb; 2(1):59-71. PubMed ID: 12113067
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Current aspects of hormonal therapy in prostate cancer].
    Altwein JE
    Helv Chir Acta; 1981 Aug; 48(3-4):391-5. PubMed ID: 7287476
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of treatment with diethylstilbestrol-polyestradiol phosphate or estramustine phosphate (estracyt) on natural killer cell activity in patients with prostatic cancer.
    Kalland T; Haukaas S
    Invest Urol; 1981 May; 18(8):437-9. PubMed ID: 7228576
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hormone therapy in prostatic cancer.
    Smith PH; Akdas A; Mason MK; Richards B; Robinson MR; de Pauw M; Sylvester R
    Acta Urol Belg; 1980 Jan; 48(1):98-105. PubMed ID: 7001876
    [No Abstract]   [Full Text] [Related]  

  • 26. [Trial of prostatic cancer treatment with estrogens associated with cyproterone].
    Hardy JC
    Acta Urol Belg; 1980 Jan; 48(1):110-2. PubMed ID: 7435344
    [No Abstract]   [Full Text] [Related]  

  • 27. Re: Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer Trials 30761 and 30762.
    deVoogt HJ; Pavone-Macaluso M; Sylvester R; Schröder FH
    J Urol; 1988 Dec; 140(6):1557. PubMed ID: 2973530
    [No Abstract]   [Full Text] [Related]  

  • 28. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
    Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
    Pummer K; Lehnert M; Stettner H; Hubmer G
    Eur Urol; 1997; 32 Suppl 3():81-5. PubMed ID: 9267791
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospective randomized Phase II trial of pegylated doxorubicin in the management of symptomatic hormone-refractory prostate carcinoma.
    Heidenreich A; Sommer F; Ohlmann CH; Schrader AJ; Olbert P; Goecke J; Engelmann UH
    Cancer; 2004 Sep; 101(5):948-56. PubMed ID: 15329902
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mitomycin C, methotrexate, and vincristine with medroxyprogesterone acetate or prednisolone for doxorubicin resistant advanced breast cancer--a randomized control study.
    Tashiro H; Nomura Y
    Anticancer Res; 1995; 15(5B):2229-37. PubMed ID: 8572630
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-dose medroxyprogesterone acetate versus estramustine in therapy-resistant prostatic cancer: a randomised study.
    Johansson JE; Andersson SO; Holmberg L
    Br J Urol; 1991 Jul; 68(1):67-73. PubMed ID: 1831397
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Hormone therapy of prostatic cancer (author's transl)].
    Altwein JE; Jacobi GH
    Urologe A; 1980 Nov; 19(6):350-7. PubMed ID: 7193368
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Continuous versus intermittent oral therapy with estramustine phosphate (Estracyt).
    Vahlensieck W; Wegner G
    Scand J Urol Nephrol Suppl; 1980; 55():147-9. PubMed ID: 6938018
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical protocols in treatment of prostatic carcinoma in Europe. The role of EORTC and other organizations].
    Newling DW
    Urologe A; 1995 Sep; 34(5):374-81. PubMed ID: 7483153
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy.
    Peeters ST; Heemsbergen WD; van Putten WL; Slot A; Tabak H; Mens JW; Lebesque JV; Koper PC
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1019-34. PubMed ID: 15752881
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of advanced prostatic carcinoma with cyproterone acetate and orchiectomy--5-year follow-up.
    Giuliani L; Pescatore D; Giberti C; Martorana G; Natta G
    Eur Urol; 1980; 6(3):145-8. PubMed ID: 7371659
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Salvage immunotherapy with subcutaneous recombinant interleukin 2 (rIL-2) and alpha-interferon (A-IFN) for stage D3 prostate carcinoma failing second-line hormonal treatment.
    Maffezzini M; Simonato A; Fortis C
    Prostate; 1996 May; 28(5):282-6. PubMed ID: 8610053
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
    Harper P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02.
    Rosenthal SA; Bae K; Pienta KJ; Sobczak ML; Asbell SO; Rajan R; Kerlin KJ; Michalski JM; Sandler HM;
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):672-8. PubMed ID: 18990504
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.